Caroline Seymour

The combination of nivolumab and azacitidine demonstrated favorable responses and overall survival in patients with relapsed/refractory acute myeloid leukemia.

Trung Nguyen, DO, MBA, discusses the evolving options for the treatment of patients with newly diagnosed advanced ovarian cancer.

Amer Karam, MD, discussed surgical options for patients with advanced-stage ovarian cancer and the emergence of neoadjuvant chemotherapy.

Stephen Oh, MD, PhD, discusses the use of ruxolitinib in patients with myelofibrosis and polycythemia vera, and emerging agents and next steps in the field of myeloproliferative neoplasms.

Mary Jo Fidler, MD, discusses the latest developments in the treatment of patients with ALK-positive lung cancer.

Oliver Dorigo, MD, PhD, discusses the promise of immunotherapy in ovarian cancer.

Jonathan S. Berek, MD, MMS, outlines the changing paradigm of ovarian cancer.

Elisabeth Diver, MD, discusses ongoing advances with PARP inhibitors in ovarian cancer.

Geoffrey Uy, MD, discusses the impact of targeted therapies on the treatment of patients with newly diagnosed acute myeloid leukemia.

Higher survival rates were observed with radical prostatectomy and adjuvant radiotherapy compared with radiotherapy and androgen deprivation therapy in men with locally advanced prostate cancer.

Ravi Vij, MD, discusses emerging treatment options for patients with newly diagnosed multiple myeloma.

Nancy Nixon, MD, discusses the retrospective study of the evolution of biosimilars in oncology, with a focus on trastuzumab and the path toward the integration of biosimilars into cancer care.

Hossein Borghaei, DO, MS, discusses current and potential therapeutic approaches for patients with non-oncogene driven lung cancer who progress on frontline treatment.

Balazs Halmos, MD, discusses the latest developments in the treatment paradigm for patients with squamous cell non–small cell lung cancer.

Low NR2F1 expression in disseminated tumor cells (DTCs) that is found in bone marrow may be indicative of developing metastatic breast cancer, according to results of a study published in Breast Cancer Research.

Jason Valent, MD, discusses the current and future landscape of relapsed/refractory multiple myeloma.

Dieter Zopf discusses the identification of effective drug combinations with regorafenib for the treatment of patients with pediatric rhabdomyosarcomas.

Syma Iqbal, MD, discusses the evolving treatment paradigm of neuroendocrine tumors.

Hope S. Rugo, MD, discusses CDK4/6 inhibition in HR-positive breast cancer, mechanisms of resistance to these drugs, and other potential pathway blockades.

Brad Kahl, MD, discusses the rapidly evolving therapeutic landscape of CLL and the novel combinations on the horizon.

Armin Ghobadi, MD, discusses the evolution and expansion of CAR T-cell therapy in oncology and how to maximize its application across liquid and solid tumors.

Nancy L. Bartlett, MD, discusses factors in treatment decisions for patients with advanced-stage Hodgkin lymphoma.

Hope S. Rugo, MD, discusses an analysis of trastuzumab biosimilars in breast cancer.

Sarah K. Tasian, MD, discusses the diagnostic and therapeutic approaches to treating patients with pediatric Philadelphia-like acute lymphoblastic leukemia.

Igor Puzanov, MD, MSCI, FACP, discusses the current and potential future utility of talimogene laherparepvec (T-VEC; Imlygic) in patients with advanced-stage melanoma.

Heinz-Josef Lenz, MD, discusses the intersection between the molecular makeup of colorectal cancer and the development of novel therapies in the treatment paradigm.

A. Jo Chien, MD, discusses emerging agents and other developments in HER2-positive breast cancer.

Gilberto Lopes, MD, discusses the KEYNOTE-042 results and ongoing developments with immunotherapy in NSCLC.

Sandy Wong, MD, discusses emerging agents being explored for the treatment of patients with multiple myeloma in late relapse.

Mikkael A. Sekeres, MD, discusses the characteristics of myelodysplastic syndrome and the evolving armamentarium of treatment.